Serum Soluble Receptors for Advanced Glycation End-Products May Predict Mortality in Microscopic Polyangiitis and Granulomatosis with Polyangiitis

This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) a...

Full description

Saved in:
Bibliographic Details
Published inYonsei medical journal Vol. 65; no. 11; pp. 651 - 660
Main Authors Yoon, Taejun, Ahn, Sung Soo, Ha, Jang Woo, Ko, Eunhee, Song, Jason Jungsik, Park, Yong-Beom, Lee, Sang-Won
Format Journal Article
LanguageEnglish
Published Korea (South) Yonsei University College of Medicine 01.11.2024
연세대학교의과대학
Subjects
Online AccessGet full text
ISSN0513-5796
1976-2437
1976-2437
DOI10.3349/ymj.2023.0466

Cover

Abstract This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model. The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094). This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA.
AbstractList This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).PURPOSEThis study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model.MATERIALS AND METHODSSerum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model.The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094).RESULTSThe median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094).This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA.CONCLUSIONThis study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA.
This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model. The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094). This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA.
Purpose: This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model. Results: The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094). Conclusion: This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA. KCI Citation Count: 0
Author Yoon, Taejun
Ahn, Sung Soo
Park, Yong-Beom
Lee, Sang-Won
Ha, Jang Woo
Ko, Eunhee
Song, Jason Jungsik
AuthorAffiliation 4 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
3 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea
2 Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
AuthorAffiliation_xml – name: 2 Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
– name: 4 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
– name: 3 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– name: 1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Taejun
  orcidid: 0000-0003-2147-3555
  surname: Yoon
  fullname: Yoon, Taejun
  organization: Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Sung Soo
  orcidid: 0000-0002-9002-9880
  surname: Ahn
  fullname: Ahn, Sung Soo
  organization: Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
– sequence: 3
  givenname: Jang Woo
  orcidid: 0000-0002-3307-5215
  surname: Ha
  fullname: Ha, Jang Woo
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Eunhee
  orcidid: 0009-0002-6528-0069
  surname: Ko
  fullname: Ko, Eunhee
  organization: Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Jason Jungsik
  orcidid: 0000-0003-0662-7704
  surname: Song
  fullname: Song, Jason Jungsik
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Yong-Beom
  orcidid: 0000-0003-4695-8620
  surname: Park
  fullname: Park, Yong-Beom
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
– sequence: 7
  givenname: Sang-Won
  orcidid: 0000-0002-8038-3341
  surname: Lee
  fullname: Lee, Sang-Won
  organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39439169$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003129791$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNpVkl1LHDEUhkOx1I_2srcll0WYbb5mxlyVRawVXLqovQ6ZzBmNZpJtkrHM3-gvbta1UiFwSPLkOZDzHqI9Hzwg9JGSBedCfpnH-wUjjC-IaJo36IDKtqmY4O0eOiA15VXdymYfHaZ0TwhrKWHv0D6XgkvayAP05xriNOLr4KbOAb4CA5scYsJDiHjZP2pvoMfnbjY62-Dxme-rdQz9ZHLCKz3jdYTemoxXIWbtbJ6x9XhlTQzJhI01eB3crP2ttdkmrH2RRe0nF0adQypHv22-ewW9R28H7RJ8eK5H6Oe3s5vT79Xlj_OL0-VlZXgrc0V7Q7tWtA3vNDsxhncMTK3LHiSTZfWsA6qFgJp3raai0YQZ0nA9yKEG4EfoeOf1cVAPxqqg7VO9DeohquXVzYWihT-pG1Hgrzt4M3Uj9AZ8jtqpTbSjjvPT09c33t4V0aOitKaScloMn58NMfyaIGU12mTAOe0hTElxWkbHaipkQT_93-yly7-xFaDaAdtvThGGF4QStY2FKrFQ21iobSz4X0NmrmA
Cites_doi 10.1097/MD.0b013e318205a4c6
10.1002/jemt.10300
10.1136/annrheumdis-2021-221795
10.1136/annrheumdis-2021-221796
10.1136/annrheumdis-2016-210942
10.1155/2019/2067353
10.1080/14397595.2018.1551107
10.1093/rheumatology/keab413
10.1186/s12865-022-00513-4
10.1016/j.crohns.2011.03.011
10.3349/ymj.2019.60.1.10
10.1002/art.22217
10.3389/fimmu.2022.931473
10.1016/j.vph.2015.06.011
10.1093/advances/nmab072
10.1001/jama.2013.13805
10.3349/ymj.2022.0435
10.1002/lt.24129
10.1136/ard.2006.054593
10.1136/ard.2008.101279
10.1373/clinchem.2016.264135
10.3390/molecules27154922
10.1186/s12891-015-0569-3
10.1016/j.bbagen.2016.11.040
10.5114/reum.2017.71638
10.1189/jlb.1012519
10.1002/art.37715
10.1016/j.redox.2021.101958
10.1186/1478-811X-7-12
10.1136/annrheumdis-2013-203255
10.3349/ymj.2021.62.4.279
ContentType Journal Article
Copyright Copyright: Yonsei University College of Medicine 2024.
Copyright: Yonsei University College of Medicine 2024 2024 Yonsei University College of Medicine
Copyright_xml – notice: Copyright: Yonsei University College of Medicine 2024.
– notice: Copyright: Yonsei University College of Medicine 2024 2024 Yonsei University College of Medicine
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3349/ymj.2023.0466
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1976-2437
EndPage 660
ExternalDocumentID oai_kci_go_kr_ARTI_10638564
PMC11519131
39439169
10_3349_ymj_2023_0466
Genre Journal Article
GrantInformation_xml – fundername: CELLTRION PHARM, Inc.
  grantid: NCR 2019-6
– fundername: Chong Kun Dang Pharmaceutical Corp
– fundername: ;
– fundername: ;
  grantid: NCR 2019-6
GroupedDBID ---
.55
.GJ
123
29R
2WC
36B
5-W
53G
5RE
8JR
8XY
9ZL
AAYXX
ACYCR
ADBBV
ADRAZ
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
CS3
DIK
DU5
E3Z
EBD
EF.
EMB
EMOBN
F5P
GROUPED_DOAJ
GX1
HYE
KQ8
L7B
M48
MK0
O5R
O5S
OK1
OVT
P2P
PGMZT
RNS
RPM
SV3
TR2
X7M
XSB
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
M~E
NPM
7X8
5PM
ID FETCH-LOGICAL-c379t-1dc1b74763ba28cc3b2ec5a763e929929d2be1a44e53b7a146a02c063af9f5ee3
IEDL.DBID M48
ISSN 0513-5796
1976-2437
IngestDate Sat Oct 26 03:19:14 EDT 2024
Thu Aug 21 18:44:00 EDT 2025
Fri Jul 11 16:55:00 EDT 2025
Thu Jan 02 22:24:17 EST 2025
Tue Jul 01 04:03:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords granulomatosis with polyangiitis
mortality
Soluble
microscopic polyangiitis
receptors for advanced glycation end products
Language English
License Copyright: Yonsei University College of Medicine 2024.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c379t-1dc1b74763ba28cc3b2ec5a763e929929d2be1a44e53b7a146a02c063af9f5ee3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Taejun Yoon and Sung Soo Ahn contributed equally to this work.
https://www.eymj.org/DOIx.php?id=10.3349/ymj.2023.0466
ORCID 0009-0002-6528-0069
0000-0003-4695-8620
0000-0002-9002-9880
0000-0003-0662-7704
0000-0002-8038-3341
0000-0002-3307-5215
0000-0003-2147-3555
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2023.0466
PMID 39439169
PQID 3119725149
PQPubID 23479
PageCount 10
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10638564
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11519131
proquest_miscellaneous_3119725149
pubmed_primary_39439169
crossref_primary_10_3349_ymj_2023_0466
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-11-01
PublicationDateYYYYMMDD 2024-11-01
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Yonsei medical journal
PublicationTitleAlternate Yonsei Med J
PublicationYear 2024
Publisher Yonsei University College of Medicine
연세대학교의과대학
Publisher_xml – name: Yonsei University College of Medicine
– name: 연세대학교의과대학
References Mukhtyar (10.3349/ymj.2023.0466_ref16) 2009; 68
Yilmaz (10.3349/ymj.2023.0466_ref19) 2011; 5
Tan (10.3349/ymj.2023.0466_ref26) 2017; 76
Masiak (10.3349/ymj.2023.0466_ref5) 2017; 55
Moroz (10.3349/ymj.2023.0466_ref10) 2003; 60
Serveaux-Dancer (10.3349/ymj.2023.0466_ref21) 2019; 2019
Antonelli (10.3349/ymj.2023.0466_ref29) 2017; 1861
Ahn (10.3349/ymj.2023.0466_ref14) 2021; 62
Pyo (10.3349/ymj.2023.0466_ref15) 2023; 64
Pullerits (10.3349/ymj.2023.0466_ref28) 2006; 54
Sharifi-Zahabi (10.3349/ymj.2023.0466_ref30) 2021; 12
Bai (10.3349/ymj.2023.0466_ref12) 2022; 23
Millet (10.3349/ymj.2023.0466_ref6) 2013; 72
Jafari Nakhjavani (10.3349/ymj.2023.0466_ref18) 2019; 29
Jennette (10.3349/ymj.2023.0466_ref1) 2013; 65
Page (10.3349/ymj.2023.0466_ref11) 2022; 61
Chen (10.3349/ymj.2023.0466_ref20) 2015; 16
Kierdorf (10.3349/ymj.2023.0466_ref31) 2013; 94
Yue (10.3349/ymj.2023.0466_ref7) 2022; 27
Dong (10.3349/ymj.2023.0466_ref9) 2022; 13
Schmidt (10.3349/ymj.2023.0466_ref23) 2015; 72
Riehl (10.3349/ymj.2023.0466_ref8) 2009; 7
Choi (10.3349/ymj.2023.0466_ref27) 2019; 60
Guillevin (10.3349/ymj.2023.0466_ref17) 2011; 90
Basta (10.3349/ymj.2023.0466_ref24) 2015; 21
Murray (10.3349/ymj.2023.0466_ref25) 2013; 310
Suppiah (10.3349/ymj.2023.0466_ref4) 2022; 81
Loomis (10.3349/ymj.2023.0466_ref22) 2017; 63
Watts (10.3349/ymj.2023.0466_ref2) 2007; 66
Robson (10.3349/ymj.2023.0466_ref3) 2022; 81
Erusalimsky (10.3349/ymj.2023.0466_ref13) 2021; 42
References_xml – volume: 90
  start-page: 19
  year: 2011
  ident: 10.3349/ymj.2023.0466_ref17
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0b013e318205a4c6
– volume: 60
  start-page: 581
  year: 2003
  ident: 10.3349/ymj.2023.0466_ref10
  publication-title: Microsc Res Tech
  doi: 10.1002/jemt.10300
– volume: 81
  start-page: 315
  year: 2022
  ident: 10.3349/ymj.2023.0466_ref3
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2021-221795
– volume: 81
  start-page: 321
  year: 2022
  ident: 10.3349/ymj.2023.0466_ref4
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2021-221796
– volume: 76
  start-page: 1566
  year: 2017
  ident: 10.3349/ymj.2023.0466_ref26
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-210942
– volume: 2019
  start-page: 2067353
  year: 2019
  ident: 10.3349/ymj.2023.0466_ref21
  publication-title: Dis Markers
  doi: 10.1155/2019/2067353
– volume: 29
  start-page: 943
  year: 2019
  ident: 10.3349/ymj.2023.0466_ref18
  publication-title: Mod Rheumatol
  doi: 10.1080/14397595.2018.1551107
– volume: 61
  start-page: 834
  year: 2022
  ident: 10.3349/ymj.2023.0466_ref11
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keab413
– volume: 23
  start-page: 42
  year: 2022
  ident: 10.3349/ymj.2023.0466_ref12
  publication-title: BMC Immunol
  doi: 10.1186/s12865-022-00513-4
– volume: 5
  start-page: 402
  year: 2011
  ident: 10.3349/ymj.2023.0466_ref19
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2011.03.011
– volume: 60
  start-page: 10
  year: 2019
  ident: 10.3349/ymj.2023.0466_ref27
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2019.60.1.10
– volume: 54
  start-page: 3898
  year: 2006
  ident: 10.3349/ymj.2023.0466_ref28
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22217
– volume: 13
  start-page: 931473
  year: 2022
  ident: 10.3349/ymj.2023.0466_ref9
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.931473
– volume: 72
  start-page: 1
  year: 2015
  ident: 10.3349/ymj.2023.0466_ref23
  publication-title: Vascul Pharmacol
  doi: 10.1016/j.vph.2015.06.011
– volume: 12
  start-page: 2157
  year: 2021
  ident: 10.3349/ymj.2023.0466_ref30
  publication-title: Adv Nutr
  doi: 10.1093/advances/nmab072
– volume: 310
  start-page: 591
  year: 2013
  ident: 10.3349/ymj.2023.0466_ref25
  publication-title: JAMA
  doi: 10.1001/jama.2013.13805
– volume: 64
  start-page: 11
  year: 2023
  ident: 10.3349/ymj.2023.0466_ref15
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2022.0435
– volume: 21
  start-page: 847
  year: 2015
  ident: 10.3349/ymj.2023.0466_ref24
  publication-title: Liver Transpl
  doi: 10.1002/lt.24129
– volume: 66
  start-page: 222
  year: 2007
  ident: 10.3349/ymj.2023.0466_ref2
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.054593
– volume: 68
  start-page: 1827
  year: 2009
  ident: 10.3349/ymj.2023.0466_ref16
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.101279
– volume: 63
  start-page: 980
  year: 2017
  ident: 10.3349/ymj.2023.0466_ref22
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2016.264135
– volume: 27
  start-page: 4922
  year: 2022
  ident: 10.3349/ymj.2023.0466_ref7
  publication-title: Molecules
  doi: 10.3390/molecules27154922
– volume: 16
  start-page: 111
  year: 2015
  ident: 10.3349/ymj.2023.0466_ref20
  publication-title: BMC Musculoskelet Disord
  doi: 10.1186/s12891-015-0569-3
– volume: 1861
  start-page: 354
  year: 2017
  ident: 10.3349/ymj.2023.0466_ref29
  publication-title: Biochim Biophys Acta Gen Subj
  doi: 10.1016/j.bbagen.2016.11.040
– volume: 55
  start-page: 230
  year: 2017
  ident: 10.3349/ymj.2023.0466_ref5
  publication-title: Reumatologia
  doi: 10.5114/reum.2017.71638
– volume: 94
  start-page: 55
  year: 2013
  ident: 10.3349/ymj.2023.0466_ref31
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.1012519
– volume: 65
  start-page: 1
  year: 2013
  ident: 10.3349/ymj.2023.0466_ref1
  publication-title: Arthritis Rheum
  doi: 10.1002/art.37715
– volume: 42
  start-page: 101958
  year: 2021
  ident: 10.3349/ymj.2023.0466_ref13
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2021.101958
– volume: 7
  start-page: 12
  year: 2009
  ident: 10.3349/ymj.2023.0466_ref8
  publication-title: Cell Commun Signal
  doi: 10.1186/1478-811X-7-12
– volume: 72
  start-page: 1273
  year: 2013
  ident: 10.3349/ymj.2023.0466_ref6
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-203255
– volume: 62
  start-page: 279
  year: 2021
  ident: 10.3349/ymj.2023.0466_ref14
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2021.62.4.279
SSID ssj0027102
Score 2.3809493
Snippet This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the...
Purpose: This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 651
SubjectTerms Adult
Aged
Aged, 80 and over
Biomarkers - blood
Female
Granulomatosis with Polyangiitis - blood
Granulomatosis with Polyangiitis - diagnosis
Granulomatosis with Polyangiitis - mortality
Humans
Male
Microscopic Polyangiitis - blood
Microscopic Polyangiitis - diagnosis
Microscopic Polyangiitis - mortality
Middle Aged
Original
Proportional Hazards Models
Receptor for Advanced Glycation End Products - blood
의학일반
Title Serum Soluble Receptors for Advanced Glycation End-Products May Predict Mortality in Microscopic Polyangiitis and Granulomatosis with Polyangiitis
URI https://www.ncbi.nlm.nih.gov/pubmed/39439169
https://www.proquest.com/docview/3119725149
https://pubmed.ncbi.nlm.nih.gov/PMC11519131
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003129791
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Yonsei Medical Journal, 2024, 65(11), , pp.651-660
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3RbtMwFLXokKa9IAYDCqwyAvGWUsdOmjygaZo2BlJQH6jYm2U79haWOSNtJfIbfDH3JulGUZEiRUkcW_Fx7HOu7XsJeccmSoXh1AWJinkgmI0C9AkShM6A1J7kwHDRoJ99jc_n4stFdHHvUqivwMVWaYfxpOZ1Of71szmCH_4jKk4u0g_NzY8xRgEfg9aLB-QhDEox6rBMJPfai-FCnoOtr-yRXZ62O1DTjdFp4Gu3jXj-u37yrwHp7DF51DNJetxBv08eWP-E7Gb9XPlT8hu6gdUNRbuXLi0FfmhvMbQOBZpKj_upf_qpbDqjHT31eTDr_L8uaKYaOqsxryXN2soBtk4LTzNcwIdbWQpDZ1XZKH9ZoFskqjxkBgPfqqyABFcLuIU23o1EB2R-dvrt5DzoIzAEhk_TZcBywzQIjphrFSbGcB1aEym4tkCr4MhDbZkSwkZcTxX0umoSGmA9yqUuspY_Izu-8vYFocylhjvmIqFBJLlEaWAWSjhtXJ7HUzEk79c1L287RxsSBAqiJQEtiWhJRGtI3gIu8toUEl1j4_mykte1BAHwGV6BDiWKIbs3a9wk_DA4C6K8rVYLydtIa8AT0yF53uF4V-C6GQxJsoHwXQIscfOJL65ap9zArEH6cvbyv5m-InvwEaLbyPia7CzrlT0ERrPUIzKIgu-j1h4watvtHwYc-V0
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Soluble+Receptors+for+Advanced+Glycation+End-Products+May+Predict+Mortality+in+Microscopic+Polyangiitis+and+Granulomatosis+with+Polyangiitis&rft.jtitle=Yonsei+medical+journal&rft.au=Yoon%2C+Taejun&rft.au=Ahn%2C+Sung+Soo&rft.au=Ha%2C+Jang+Woo&rft.au=Ko%2C+Eunhee&rft.date=2024-11-01&rft.eissn=1976-2437&rft.volume=65&rft.issue=11&rft.spage=651&rft_id=info:doi/10.3349%2Fymj.2023.0466&rft_id=info%3Apmid%2F39439169&rft.externalDocID=39439169
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon